Aryl oxime-piperazines useful as ccr5 antagonists

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 211/58 (2006.01) A61K 31/496 (2006.01) A61K 31/506 (2006.01) A61P 31/18 (2006.01) C07D 401/04 (2006.01) C07D 401/06 (2006.01) C07D 401/14 (2006.01)

Patent

CA 2442210

In one embodiment, this invention provides a novel class of aryl oxime- piperazine compounds as antagonists of the CCR5 receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more of diseases associated with the CCR5 receptor. An illustrative inventive compound is shown below: (Formula I).

Dans une forme de réalisation, l'invention concerne une nouvelle classe de composés d'aryloxime-pipérazine utiles comme antagonistes du récepteur CCR5, des procédés de préparation de ces composés, des compositions pharmaceutiques contenant un ou plusieurs de ces composés, des procédés de préparation de formulations pharmaceutiques contenant un ou plusieurs de ces composés, et des traitements visant à prévenir ou à soulager une ou plusieurs maladies associées au récepteur CCR5. Un tel composé est représenté par la formule I :

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Aryl oxime-piperazines useful as ccr5 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl oxime-piperazines useful as ccr5 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl oxime-piperazines useful as ccr5 antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2068537

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.